JP Morgan Cazenove reiterated Shire PLC (LON:SHP) to Overweight in a report released today.
- Updated: September 22, 2016
JP Morgan Cazenove has reiterated Shire PLC (LON:SHP) to Overweight in a report released on 09/23/2016.
Previously on 9/19/2016, Liberum Capital reported on Shire PLC (LON:SHP) held steady the target price at 5,500.00GBX. At the time, this indicated a possible upside of 0.08%.
Just yesterday Shire PLC (LON:SHP) traded 0.21% higher at 5,191.50GBX. Shire PLC’s 50-day moving average is 4,978.00GBX and its 200-day moving average is 4,460.91GBX. The last closing price is up 16.57% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 54,541 shares of SHP traded hands, down from an average trading volume of 2,127,230
Recent Performance Chart
Shire PLC has 52 week low of 2,707.19GBX and a 52 week high of 5,216.00GBX with a PE ratio of 32.42 and has a market capitalization of 0 GBX.
In addition to JP Morgan Cazenove reporting its stock price target, a total of 18 brokers have issued a research note on the company. The average stock price target is 73.73GBX with 6 brokers rating the stock a strong buy, 16 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Shire PLC (LON:SHP)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.